PSP Research LLC Takes Position in Celcuity, Inc. $CELC

PSP Research LLC purchased a new stake in shares of Celcuity, Inc. (NASDAQ:CELC) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund purchased 5,244 shares of the company’s stock, valued at approximately $523,000.

Other institutional investors have also made changes to their positions in the company. Ogorek Anthony Joseph NY ADV acquired a new stake in shares of Celcuity during the 3rd quarter valued at about $27,000. US Bancorp DE lifted its holdings in shares of Celcuity by 25.4% during the 3rd quarter. US Bancorp DE now owns 706 shares of the company’s stock valued at $35,000 after buying an additional 143 shares during the last quarter. NBC Securities Inc. acquired a new stake in shares of Celcuity during the 4th quarter valued at about $99,000. Everhart Financial Group Inc. acquired a new stake in shares of Celcuity during the 4th quarter valued at about $209,000. Finally, Saxony Capital Management LLC acquired a new stake in shares of Celcuity during the 4th quarter valued at about $251,000. 63.33% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on CELC. Wall Street Zen cut Celcuity from a “hold” rating to a “sell” rating in a research report on Saturday, April 25th. Craig Hallum reaffirmed a “buy” rating and set a $189.00 target price on shares of Celcuity in a research report on Monday, May 4th. Stifel Nicolaus set a $150.00 target price on Celcuity in a research report on Monday, May 4th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Celcuity in a research report on Monday, April 20th. Finally, Citigroup reaffirmed an “outperform” rating on shares of Celcuity in a research report on Monday, May 4th. Eleven analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $149.30.

Celcuity Stock Performance

Shares of NASDAQ CELC opened at $131.09 on Wednesday. The company has a quick ratio of 12.31, a current ratio of 12.31 and a debt-to-equity ratio of 6.04. The business’s 50 day moving average is $119.52 and its two-hundred day moving average is $107.75. The company has a market cap of $6.39 billion, a P/E ratio of -33.61 and a beta of 0.09. Celcuity, Inc. has a 12 month low of $10.26 and a 12 month high of $151.02.

Celcuity (NASDAQ:CELC) last issued its quarterly earnings results on Thursday, May 14th. The company reported ($0.97) EPS for the quarter, topping the consensus estimate of ($1.07) by $0.10. On average, equities analysts expect that Celcuity, Inc. will post -3.87 EPS for the current year.

Insider Activity at Celcuity

In other Celcuity news, Director Richard E. Buller sold 9,000 shares of Celcuity stock in a transaction that occurred on Monday, May 4th. The stock was sold at an average price of $140.46, for a total value of $1,264,140.00. Following the transaction, the director directly owned 6,760 shares of the company’s stock, valued at $949,509.60. The trade was a 57.11% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director David Dalvey sold 25,000 shares of Celcuity stock in a transaction that occurred on Monday, May 4th. The stock was sold at an average price of $140.68, for a total value of $3,517,000.00. Following the completion of the transaction, the director directly owned 65,000 shares in the company, valued at approximately $9,144,200. This represents a 27.78% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 37,000 shares of company stock worth $5,111,950. Company insiders own 13.33% of the company’s stock.

Celcuity Company Profile

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.